Roche stock holds steady as investors await fresh 2026 updates

Roche (CH0012032048) is still trading against a 2025 base that matters for the next move: sales were CHF 60.5 billion in 2025, core operating profit reached CHF 19.5 billion, and pharmaceuticals sales came in at CHF 46.2 billion for the year. Those figures set the backdrop for Roche stock as the market waits for the next dated update from the Swiss group.

2025 sales set the base

Roche reported 2025 sales of CHF 60.5 billion and core operating profit of CHF 19.5 billion, giving the stock a clear fundamental reference point for 2026 trading. Pharmaceuticals sales accounted for CHF 46.2 billion in 2025, while diagnostics contributed CHF 14.3 billion, so the business mix remained heavily weighted toward drugs.

The year-on-year comparison also gives investors a concrete lens: pharmaceuticals sales were up 7% at constant exchange rates in 2025, according to Roche, while diagnostics sales were up 1% at constant exchange rates. That split matters because Roche stock often reacts more to the pharmaceuticals engine than to diagnostics growth.

Profit and mix matter

Core operating profit of CHF 19.5 billion in 2025 provides the second key yardstick, especially after the company’s CHF 60.5 billion sales base. A margin discussion follows naturally from those figures, and Roche highlighted its 2025 operating performance as a driver for the next phase of the pipeline and launch cycle.

For a large-cap healthcare name, the comparison is straightforward: CHF 60.5 billion in sales against CHF 19.5 billion in core operating profit leaves investors focused on conversion, not just top-line growth. The 2025 numbers also give a cleaner read on how much room Roche has to absorb launch costs, trial spending, and currency noise in 2026.

What Roche sells

The product side still revolves around the company’s core pharmaceuticals portfolio, which delivered CHF 46.2 billion in 2025 sales. Diagnostics remained a smaller but still material contributor at CHF 14.3 billion, and that split helps explain why the market tends to prioritize updates from the drug pipeline and major franchise launches.

Roche stock is therefore driven less by a single product label than by the combined performance of its major therapeutic areas. The 2025 annual figures show a company with a large, diversified base and enough scale to make even modest changes in growth or margin visible in the share price.

Stock level and venue

Roche’s primary listing is on SIX Swiss Exchange, and the stock should be read in Swiss franc terms rather than translated into a different currency frame. The latest quoted level was not available in the source set for this call, so the most useful market reference in this article remains the 2025 revenue and profit base.

That leaves investors with a simple marker: CHF 60.5 billion in sales, CHF 19.5 billion in core operating profit, and CHF 46.2 billion in pharmaceuticals revenue for 2025. Those three numbers define the starting point for Roche stock in 2026.